Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
11.59
+0.61 (5.56%)
At close: May 12, 2025, 4:00 PM
12.59
+1.00 (8.63%)
After-hours: May 12, 2025, 7:25 PM EDT
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $29.38M in the quarter ending March 31, 2025, a decrease of -22.70%. This brings the company's revenue in the last twelve months to $143.68M, up 15.38% year-over-year. In the year 2024, Arcturus Therapeutics Holdings had annual revenue of $152.31M, down -8.69%.
Revenue (ttm)
$143.68M
Revenue Growth
+15.38%
P/S Ratio
2.05
Revenue / Employee
$816,364
Employees
176
Market Cap
314.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARCT News
- 4 hours ago - Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 20 days ago - Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire
- 4 weeks ago - Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire
- 2 months ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress - Business Wire
- 2 months ago - Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025 - Business Wire
- 2 months ago - Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 - Business Wire
- 3 months ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire